INVO Bioscience, Inc. announced that on March 31, 2023, Jeffrey Segal MD submitted his resignation as a director of the Company. Dr. Segal's resignation was not because of any disagreements with the Company on matters relating to its operations, policies and practices.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.751 USD | -1.18% | -9.63% | -44.07% |
05-15 | INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-18 | Top Premarket Decliners | MT |
1st Jan change | Capi. | |
---|---|---|
-44.07% | 2.89M | |
-3.92% | 187B | |
+0.01% | 109B | |
-2.85% | 69.22B | |
-6.43% | 46.36B | |
+13.44% | 46.19B | |
+8.48% | 42.44B | |
+18.40% | 30.84B | |
+19.69% | 25.73B | |
-8.29% | 23.3B |
- Stock Market
- Equities
- INVO Stock
- News INVO Bioscience, Inc.
- INVO Bioscience, Inc. Announces Resignation of Jeffrey Segal as A Director